Polymorphism of TP53 codon 72 showed no association with breast cancer in Iranian women

Cancer Genetics and Cytogenetics

Volumn 173, Issue 1, 2007, Pages 38-42

  Khadang, Baharak ^a   Fattahi, Mohammad Javad ^a   Talei, Abdolrasol ^b   Dehaghani, Alamtaj Samsami ^b   Ghaderi, Abbas ^a,b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROLINE; PROTEIN P53;

ADULT; AGED; ALLELE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CODON; CONTROLLED STUDY; DNA EXTRACTION; DNA POLYMORPHISM; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; HISTOPATHOLOGY; HOMOZYGOSITY; HUMAN; IRAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; BREAST NEOPLASMS; CODON; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; IRAN; MIDDLE AGED; POLYMORPHISM, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

ALIAS;

EID: 33846585408     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2006.09.010     Document Type: Article

References (46)

1. Berns E.M., van Staveren I.L., Look M.P., Smid M., Klijn J.G.M., and Foekens J.A. Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer. Br J Cancer 77 (1998) 1130-1136
2. Goldhirsch A. Breast cancer. In: Cavalli F., Hansen H., and Kaye S.B. (Eds). Textbook of medical oncology (2000), Martin Dunitz, London 137-183
3. Hollstein M., Sidransky D., Vogelstein B., and Harris C.C. p53 mutations in human cancers. Science 253 (1991) 49-53
4. Wu M.T., Chen M.C., and Wu D.C. Influences of lifestyle habits and p53 codon 72 and p21 codon 31 polymorphisms on gastric cancer risk in Taiwan. Cancer Lett 205 (2004) 61-68
5. Powell B.L., Staveren I.L., Roosken P., Grieu F., Berns E.M., and Iacopetta B. Associations between common polymorphisms in TP53 and p21 WAF1/Cip1 and phenotypic features of breast cancer. Carcinogenesis 23 (2002) 311-315
6. Keshava C., Frye B.L., Wolff M.S., McCanlies E.C., and Weston A. Waf-1 (p21) and p53 polymorphisms in breast cancer. Cancer Epidemiol Biomarkers Prev 11 (2002) 127-130 [Erratum in: Cancer Epidemiol Biomarkers Prev 2004;13:1682]
7. Roh J.W., Kim J.W., Park N.H., Song Y.S., Park I.A., Park S.Y., Kang S.B., and Lee H.P. p53 and p21 genetic polymorphisms and susceptibility to endometrial cancer. Gynecol Oncol 93 (2004) 499-505
8. Huang S.P., Wu W.J., Chang W.S., Wu M.T., Chen Y.Y., Chen Y.J., Yu C.C., Wu T.T., Lee Y.H., Huang J.K., and Huang C.H. p53 codon 72 and P21 codon 31 polymorphisms in prostate cancer. Cancer Epidemiol Biomarkers Prev 13 (2004) 2217-2224
9. Lee S.A., Kim J.W., Roh J.W., Choi J.Y., Lee K.M., Yoo K.Y., Song Y.S., and Kang D. Genetic polymorphisms of GSTM1, p21, p53 and HPV infection with cervical cancer in Korean women. Gynecol Oncol 93 (2004) 14-18
10. Zhu Z.Z., Cong W.M., Zhu G.S., Liu S.F., Xian Z.H., Wu W.Q., Zhang X.Z., Wang Y.H., and Wu M.C. Association of p53 codon 72 polymorphism with genetic susceptibility to hepatocellular carcinoma in a Chinese population. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 22 (2005) 632-635
11. Wang Y., Kringen P., Kristensen G.B., Holm R., Baekelandt M.M., Olivier M., Skomedal H., Hainaut P., Trope C.G., Abeler V.M., Nesland J.M., Borresen Dale A.L., and Helland A. Effect of the codon 72 polymorphisms (c.215 G>C, p.Arg 72 Pro) in combination with somatic sequences variants in TP53 gene on survival in patients with advanced ovarian carcinoma. Hum Mutat 24 (2004) 21-34 [Erratum in: Hum Mutat 2006;27:209-10]
12. Hogdall E.V., Hogdall C.K., Christensen L., Glud E., Blaakaer J., Bock J.E., Vuust J., Norgaard-Pedersen B., and Kjaer S.K. Distribution of p53 codon 72 polymorphisms in ovarian tumour patients and their prognostic significance in ovarian cancer patients. Anticancer Res 22 (2002) 1859-1864
13. Oren M. Decision making by p53: life, death and cancer. Cell Death Differ 10 (2003) 431-442
14. Bautista S., and Theillet C. p53 mutations in breast cancer, incidence and relations to tumor aggressiveness and evolution of the disease. Pathol Biol (Paris) 45 (1997) 882-892
15. Donehower L.A. p53 guardian and suppressor of longevity?. Exp Gerontol 40 (2005) 7-9
16. Zehbe I., Voglino G., Wilander E., Genta F., and Tommasino M. Codon 72 polymorphism of p53 and its association with cervical cancer. Lancet 354 (1999) 218-219
17. Jain N., Singh V., Hedau S., Kumar S., Daga M.K., Dewan R., Murthy N.S., Husain S.A., and Das B.C. Infection of human papillomavirus type 18 and p53 codon 72 polymorphism in lung cancer patients from India. Chest 128 (2005) 3999-4007
18. Matakidou A., Eisen T., and Houlston R.S. TP53 polymorphisms and lung cancer risk a systemic review and meta-analysis. Mutagenesis 18 (2003) 377-385
19. Dumont P., Leu J.I., Della Pietra A.C., George D.L., and Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33 (2003) 357-365
20. Buyru N., Tigli H., and Dalay N. p53 codon 72 polymorphism in breast cancer. Oncol Rep 10 (2003) 711-714
21. Langerød A., Bukholm I.R., Bregåard A., Lønning P.E., Andersen T.I., Rognum T.O., Meling G.I., Lothe R.A., and Børresen-Dale A.L. The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol Biomarkers Prev 11 (2002) 1684-1688
22. Papadakis E.N., Dokianakis D.N., and Spandidos D.A. p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun 3 (2000) 389-392
23. Tommiska J., Eerola H., Heinonen M., Salonen L., Kaare M., Tallila J., Ristimaki A., von Smitten K., Aittomaki K., Heikkila P., Blomqvist C., and Nevanlinna H. Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res 11 (2005) 5098-5103
24. Toruner G.A., Ucar A., Tez M., Cetinkaya M., Ozen H., and Ozcelik T. p53 codon 72 polymorphism in bladder cancer: no evidence of association with increased risk of invasiveness. Urol Res 29 (2001) 393-395
25. Santos A.M., Sousa H., Catarino R., Pinto D., Pereira D., Vasconcelos A., Matos A., Lopes C., and Medeiros R. TP53 codon 72 polymorphism and risk for cervical cancer in Portugal. Cancer Genet Cytogenet 159 (2005) 143-147
26. Agorastos T., Masouridou S., Lambropoulos A.F., Chrisafi S., Miliaras D., Pantazis K., Constantinides T.C., Kotsis A., and Bontis I. p53 codon 72 polymorphism and correlation with ovarian and endometrial cancer in Greek women. Eur J Cancer Prev 13 (2002) 277-280
27. Leiros G.J., Galliano S.R., Sember M.E., Kahn T., Schwarz E., and Eiguchi K. Detection of human papillomavirus DNA and p53 codon 72 polymorphism in prostate carcinomas of patients from Argentina. BMC Urol 5 (2005) 15
28. Siddique M.M., Balram C., Fiszer-Maliszewska L., Aggarwal A., Tan A., Tan P., Soo K.C., and Sabapathy K. Evidence for selective expression of the p53 codon 72 polymorphs: implications in cancer development. Cancer Epidemiol Biomarkers Prev 14 (2005) 2245-2252
29. Storey A., Thomas M., Kalita A., Harwood C., Gardiol D., Mantovani F., Breuer J., Leigh I.M., Matlashewski G., and Banks L. Role of p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 393 (1998) 229-234
30. Crook T., Ludwig R.L., Marston N.J., Willkomm D., and Vousden K.H. Sensitivity of p53 lysine mutants to ubiquitin-directed degradation targeted by human papillomavirus E6. Virology 217 (1996) 285-292
31. Madeleine M.M., Shera K., Schwartz S.M., Daling J.R., Galloway D.A., Wipf G.C., Carter J.J., McKnight B., and McDougall J.K. The p53 Arg 72 Pro polymorphism, human papillomavirus, and invasive squamous cell cervical cancer. Cancer Epidemiol Biomarkers Prev 9 (2000) 225-227
32. Tenti P., Vesentini N., Rondo Spaudo M., Zappatore R., Migliora P., Carnevali L., and Ranzani G.N. p53 codon 72 polymorphism does not affect the risk of cervical cancer in patients from northern Italy. Cancer Epidemiol Biomarkers Prev 9 (2000) 435-438
33. Wang Y.C., Lee H.S., Chen S.K., Yang S.C., and Chen C.Y. Analysis of K-ras gene mutations in lung carcinomas: correlation with gender, histological subtypes, and clinical outcome. J Cancer Res Clin Oncol 124 (1998) 517-522
34. Pierce L.M., Sivaraman L., Chang W., Lum A., Donlon T., Seifried A., Wilkens L.R., Lau A.F., and Le Marchand L. Relationships of TP53 codon 72 and HRAS1 polymorphisms with lung cancer risk in an ethnically diverse population. Cancer Epidemiol Biomarkers Prev 9 (2000) 1199-1204
35. Sayhan N., Yazici H., Budak M., Bitisik O., and Dalay N. p53 codon 72 genotypes in colon cancer: association with human papillomavirus infection. Res Commun Mol Pathol Pharmacol 109 (2001) 25-34
36. Kuroda Y., Tsukino H., Nakao H., Imai H., and Katoh T. p53 codon 72 polymorphism and urothelial cancer risk. Cancer Lett 189 (2003) 77-83
37. Soulitzis N., Sourvinos G., Dokianakis D.N., and Spandidos D.A. p53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett 179 (2002) 175-183
38. Dokianakis D.N., Koumantaki E., Billiri K., and Spandidos D.A. p53 codon 72 polymorphism as a risk factor in the development of HPV-associated non-melanoma skin cancers in immunocompetent hosts. Int J Mol Med 5 (2000) 405-409
39. Wang-Gohrke S., Rebbeck T.R., Besenfelder W., Kreienberg R., and Runnebaum I.B. p53 germline polymorphisms are associated with an increased risk for breast cancer in German women. Anticancer Res 18 (1998) 2095-2099
40. Sjalander A., Birgander R., Hallmans G., Cajander S., Lenner P., Athlin L., Beckman G., and Beckman L. p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis 17 (1996) 1313-1316
41. Papadakis E.N., Dokianakis D.N., and Spandidos D.A. p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun 3 (2000) 389-392
42. Suspitsin E.N., Buslov K.G., Grigoriev M.Y., Ishutkina J.G., Ulibina J.M., Gorodinskaya V.M., Pozharisski K.M., Berstein L.M., Hanson K.P., Togo A.V., and Imyanitov E.N. Evidence against involvement of p53 polymorphism in breast cancer predisposition. Int J Cancer 103 (2003) 431-433
43. Weston A., Pan C.F., Ksieski H.B., Wallenstein S., Berkowitz G.S., Tartter P.I., Bleiweiss I.J., Brower S.T., Senie R.T., and Wolff M.S. p53 haplotype determination in breast cancer. Cancer Epidemiol Biomarkers Prev 6 (1997) 105-112
44. Li T., Lu Z.M., Guo M., Wu Q.J., Chen K.N., Xing H.P., Mei Q., and Ke Y. p53 codon 72 polymorphism (C/G) and the risk of human papillomavirus-associated carcinomas in China. Cancer 95 (2002) 2571-2576
45. Makni H., Franco E.L., Kaiano J., Villa L.L., Labrecque S., Dudley R., Storey A., and Matlashewski G. p53 polymorphism in codon 72 and risk of human papillomavirus-induced cervical cancer: effect of inter-laboratory variation. Int J Cancer 87 (2000) 528-533
46. Farjadian S., Asadi E., Doroudchi M., Dehaghani A.S., Tabei S.Z., Kumar V.P., and Ghaderi A. High risk HPV types in southern Iranian patients with cervical cancer. Pathol Oncol Res 9 (2003) 121-125